Author/Authors :
Taheri, Mohammad Urogenital Stem Cell Research Center - Shahid Beheshti University of Medical Sciences, Tehran , Noroozi, Rezvan Department of Medical Genetics - Shahid Beheshti University of Medical Sciences, Tehran - Phytochemistry Research Center - Shahid Beheshti University of Medical Sciences, Tehran , Rakhshan, Azadeh Cancer Research Center - Shahid Beheshti University of Medical Sciences, Tehran , Ghanbari, Molud Department of Clinical Biochemistry - Faculty of Medicine - Shahid Beheshti University of Medical Sciences, Tehran , Omrani, Mir Davood Urogenital Stem Cell Research Center - Shahid Beheshti University of Medical Sciences, Tehran , Ghafouri-Fard, Soudeh Department of Medical Genetics - Shahid Beheshti University of Medical Sciences, Tehran
Abstract :
Purpose: To evaluate the role of Interleukin-6 (IL-6) single nucleotide polymorphisms in prostate cancer (PCa)
and benign prostate hyperplasia (BPH).
Materials and Methods: We genotyped two IL-6 intronic variants (rs1800795 and rs2069845) in PCa cases, BPH
cases and healthy men referred to Labbafinejad and Shohadaye Tajrish Medical Centers using tetra ARMS-PCR
method.
Results: The study included 130 PCa cases, 200 BPH cases and 200 healthy men. The C allele of rs1800795 was
associated with PCa risk in the assessed population (OR (95% CI) = 1.45 (1.06-1.98)). However, the frequency
of rs2069845 variants was not significantly different between PCa, BPH and control groups. The A C haplotype
(rs2069845 and rs1800795 respectively) was associated with PCa and BPH risk (OR (95% CI) = 1.67 (1.12- 2.48);
or (95% CI)= 1.78 (1.25 – 2.54)). Besides, the A G haplotype (rs2069845 and rs1800795 respectively) has a
protective effect against both PCa and BPH in the assessed population (OR (95% CI) = 0.63 (0.46-0.87); or (95%
CI)= 0.6 (0.45-0.79)).
Conclusion: Consequently, the results of the current study provide further evidence for contribution of IL-6 in
prostate cancer.
